A detailed history of First Light Asset Management, LLC transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, First Light Asset Management, LLC holds 1,384,768 shares of BCYC stock, worth $31.4 Million. This represents 2.55% of its overall portfolio holdings.

Number of Shares
1,384,768
Previous 1,193,051 16.07%
Holding current value
$31.4 Million
Previous $29.7 Million 5.65%
% of portfolio
2.55%
Previous 2.32%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.02 - $24.69 $3.84 Million - $4.73 Million
191,717 Added 16.07%
1,384,768 $28 Million
Q1 2024

May 15, 2024

SELL
$16.75 - $26.1 $5.99 Million - $9.33 Million
-357,420 Reduced 23.05%
1,193,051 $29.7 Million
Q4 2023

Feb 14, 2024

SELL
$13.29 - $22.2 $2.51 Million - $4.2 Million
-188,978 Reduced 10.86%
1,550,471 $28 Million
Q2 2023

Aug 14, 2023

BUY
$18.95 - $28.67 $19.7 Million - $29.8 Million
1,040,121 Added 148.73%
1,739,449 $44.4 Million
Q1 2023

May 15, 2023

BUY
$20.02 - $31.37 $57,977 - $90,847
2,896 Added 0.42%
699,328 $14.9 Million
Q4 2022

Feb 14, 2023

SELL
$20.37 - $32.9 $168,846 - $272,708
-8,289 Reduced 1.18%
696,432 $20.6 Million
Q3 2022

Nov 14, 2022

BUY
$17.49 - $28.44 $7,678 - $12,485
439 Added 0.06%
704,721 $16.4 Million
Q2 2022

Aug 12, 2022

SELL
$12.95 - $46.99 $2.41 Million - $8.74 Million
-185,892 Reduced 20.88%
704,282 $11.8 Million
Q1 2022

May 13, 2022

SELL
$40.12 - $59.5 $4.44 Million - $6.58 Million
-110,609 Reduced 11.05%
890,174 $39.1 Million
Q4 2021

Feb 14, 2022

BUY
$41.7 - $61.14 $11.2 Million - $16.4 Million
268,052 Added 36.58%
1,000,783 $60.9 Million
Q3 2021

Nov 12, 2021

BUY
$27.95 - $44.24 $20.5 Million - $32.4 Million
732,731 New
732,731 $30.5 Million

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $673M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track First Light Asset Management, LLC Portfolio

Follow First Light Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Light Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on First Light Asset Management, LLC with notifications on news.